Stock Research: Daewoong Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Daewoong Pharmaceutical

KOSE:A069620 KR7069620003
35
  • Value
    12
  • Growth
    76
  • Safety
    Safety
    36
  • Combined
    24
  • Sentiment
    53
  • 360° View
    360° View
    35
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Daewoong Pharma manufactures and distributes pharmaceuticals. It operates in the pharmaceutical industry, producing drugs for various treatments. The company distributes its products domestically and internationally. In the last fiscal year, the company had a market cap of $1,374 million, profits of $497 million, and revenue of $963 million. The number of employees is not available.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Daewoong Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Daewoong Pharmaceutical. The consolidated Growth Rank has a good rank of 76, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 76% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 53, which means that professional investors are more optimistic about the stock than for 53% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 36, which means that the share price of Daewoong Pharmaceutical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 64% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 12, which means that the company has a financing structure that is riskier than those of 88% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
36 34 40 27
Growth
76 98 43 23
Safety
Safety
12 13 14 8
Sentiment
53 94 67 20
360° View
360° View
35 30 23 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
84 88 93 5
Opinions Change
50 50 50 4
Pro Holdings
n/a 62 38 63
Market Pulse
25 84 61 86
Sentiment
53 94 67 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
36 34 40 27
Growth
76 98 43 23
Safety Safety
12 13 14 8
Combined
24 1 12 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
62 44 53 23
Price vs. Earnings (P/E)
67 65 74 52
Price vs. Book (P/B)
28 24 31 24
Dividend Yield
30 27 26 21
Value
36 34 40 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
55 59 52 47
Profit Growth
98 100 87 40
Capital Growth
16 87 40 27
Stock Returns
74 80 13 51
Growth
76 98 43 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
11 30 13 14
Refinancing
16 8 5 19
Liquidity
55 40 41 14
Safety Safety
12 13 14 8

Similar Stocks

Discover high‑ranked alternatives to Daewoong Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

AMOREPACIFIC

KOSE:A002790
Country: South Korea
Industry: Personal Products
Size: Medium
Full Stock Analysis

NH Investment & Securities

KOSE:A005940
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Medium
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.